財團法人生物技術開發中心( Development Center for Biotechnology, 簡稱：生技中心、DCB )創立於1984年，是政府與民間共同捐助成立之非營利事業組織。生技中心創立宗旨為配合產、官、學、研各界，建構生技醫藥產業所需的重要環境設施、開發關鍵生物技術、培植延攬專業人才，以加速我國生物技術產業發展為主要任務。 生技中心以「生技產業最佳夥伴」自許，在我國生技醫藥產業價值鏈中扮演第二棒之「扶育加值」角色，承接第一棒學研界之新藥探索成果、引進國外之創新技術或先導藥品，經由本中心進行臨床前開發與加值後，再移轉至第三棒生技醫藥廠商，進而將研發成果導向商品化。本中心可透過技術引進、策略聯盟、合作研究、委託服務、技術移轉或成立衍生公司等模式進行合作，以充分整合運用生技研究資源，加速提升我國生技醫藥產業之產值，共創生技醫藥新價值，並向全球市場邁進。

Mission & Objectives The Development Center for Biotechnology (DCB) of Taiwan is a nonprofit organization founded in 1984, based on government grants and private donations. DCB's mission is to accelerate the development of Taiwan's biotech-pharma industry, by accomplishing the main objectives of building infrastructures, developing key technologies, promoting cooperation and industrialization, and training talented workforces, in coordination with governmental, industrial, and academic institutions. DCB is a value-adding partner for biotech-pharma companies of Taiwan. It plays the role of a "second-runner" in the relay-race of new drug development in Taiwan, by adding values to drug leads licensed from the "first-runner" - local or foreign companies, research institutes and universities. DCB adds values through preclinical development efforts ranging from medicinal chemistry and lead optimization to pharmacology and safety studies, which eventually lead to IND-filings and approvals. The resulting drug candidates are then licensed out to the "next-runner" in the relay - companies in the biotech-pharma industry - for clinical trials and the ultimate goal of product commercialization. In response to customer needs, DCB also facilitates technology cooperation and product commercialization processes, by employing suitable business models covering: patent licensing, technology transfer, strategic alliance, research collaboration, contract service, and spin-out venture. The objective is to help create win-win opportunities for partnership stakeholders with optimized coordination and integration of resources in Taiwan, and eventually, to help domestic companies expand business in the global market. Positioning & Vision In line with the government’s biotech-pharma development policy, which emphasizes value-addition and knowledge-basis, DCB positions itself as a "Preclinical Value-Adding R&D and Integrated Service Center for Biopharmaceuticals" to provide integrated services ranging from R&D to business development. This role is to be fulfilled by devoting concerted efforts on preclinical developments of protein, small-molecule and botanical drug leads, and setting top priorities on obtaining Investigational New Drug (IND) approvals from domestic and foreign regulatory agencies. DCB is dedicated to realizing the vision of becoming a "Leading Organization for Resource Integration, Value Creation and Biopharmaceutical Development". This is to be achieved by building world-caliber infrastructures, establishing key technologies for preclinical development, and fostering growths of highly-trained technology and business teams. In the long run, these efforts should lead to success stories of new drug development in Taiwan, and result in vigorous growth and prosperity for Taiwan's biotech-pharma industry.